PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 792 participants.

Also called NCT05387954

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 792 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05387954
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05387954. Randomized; single masking; primary purpose prevention. Start 2023-07-07 (actual); primary completion 2031-07-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
Acronym
CLOSE-2
Condition
Cryptogenic Ischemic Stroke
Condition
Patent Foramen Ovale
Intervention (Procedure)
Transcatheter PFO closure
Intervention (Drug)
Oral Anticoagulant, Direct-Acting
Intervention (Drug)
Antiplatelet therapy
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Ministry of Health, France (class: other government)
Collaborator
W.L.Gore & Associates (class: industry)
Collaborator
Abbott (class: industry)
Collaborator
Occlutech International AB (class: industry)
Collaborator
Centre Hospitalier St Anne (class: other)

Record details

Record id
cardio:ct-nct05387954
Content hash
cf113a509b018d031c03871bc7502da3d9482df4ec1cbce134d9730d3ebdc0de